Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems
Gregory W Mattingly1, Richard H Anderson2
11Washington University School of Medicine,Department of Psychiatry and Behavioral Neurosciences,St. Charles,Missouri,USA.
Abstract:
Our knowledge and understanding of the underlying neurobiology and symptomatic expression of ADHD has advanced dramatically over the past decade. Associated with these advances has been a similar explosion of new treatment options to individualize treatment for our patients. This article will: ∙ review strategies to measure ADHD symptoms and functional difficulties while seeking to achieve full symptomatic remission throughout the day ∙ summarize recent findings regarding the management and prioritization of ADHD and comorbid conditions and ∙ discuss the various pharmacologic treatment options with a focus on recently developed molecules and novel delivery systems.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Modified-Release Drug Delivery Systems: Classification
Drug Therapy
Antianxiety Medications
Oral Drug Delivery Systems: Introduction
Modified-Release Drug Delivery Systems: Influencing Factors
